Literature DB >> 8233493

Biochemical basis of aminoglycoside ototoxicity.

J Schacht1.   

Abstract

The basis for the development of a rational explanation of aminoglycoside toxicity now appears to exist. The acute effects of these drugs are primarily based on calcium antagonism and block of ion channels. The chronic toxicity requires metabolism, and the expression of tissue-specific toxicity is a balance between synthesis of the toxin and its detoxification. Further investigations into the nature of the toxic metabolite should allow us to combine this information with previously established intracellular actions of aminoglycosides to create a unified hypothesis of action. The ability of glutathione to block toxin formation or to increase detoxification (or both) may have clinical implications for the prevention of aminoglycoside-induced ototoxicity. The clinical use of aminoglycosides has somewhat decreased over the last decade because of the introduction of the less toxic cephalosporins of the third generation and the quinolones, which are effective against Pseudomonas infections. Development of bacterial resistance against aminoglycosides is another factor, although resistance to the cephalosporins is also rapidly becoming a serious problem that eventually will limit their usefulness. Only through a detailed knowledge of the molecular basis of toxicity can we rationally pursue the development of new aminoglycosides with less ototoxic and nephrotoxic potential and devise treatments that will prevent the adverse side effects of these antibiotics.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8233493

Source DB:  PubMed          Journal:  Otolaryngol Clin North Am        ISSN: 0030-6665            Impact factor:   3.346


  15 in total

Review 1.  Pharmacokinetic and pharmacodynamic issues in the treatment of bacterial infectious diseases.

Authors:  P S McKinnon; S L Davis
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-03-10       Impact factor: 3.267

2.  Manganese is toxic to spiral ganglion neurons and hair cells in vitro.

Authors:  Dalian Ding; Jerome Roth; Richard Salvi
Journal:  Neurotoxicology       Date:  2010-12-21       Impact factor: 4.294

Review 3.  Drug-induced tinnitus and other hearing disorders.

Authors:  H Seligmann; L Podoshin; J Ben-David; M Fradis; M Goldsher
Journal:  Drug Saf       Date:  1996-03       Impact factor: 5.606

4.  Distribution of gentamicin in the guinea pig inner ear after local or systemic application.

Authors:  Shun-Ichi Imamura; Joe C Adams
Journal:  J Assoc Res Otolaryngol       Date:  2003-06

5.  Use of a fluorescence assay to determine relative affinities of semisynthetic aminoglycosides to small RNAs representing bacterial and mitochondrial A sites.

Authors:  Prabuddha Waduge; Girish C Sati; David Crich; Christine S Chow
Journal:  Bioorg Med Chem       Date:  2019-09-13       Impact factor: 3.641

6.  Effects of salicylates and aminoglycosides on spontaneous otoacoustic emissions in the Tokay gecko.

Authors:  C E Stewart; A J Hudspeth
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-04       Impact factor: 11.205

7.  Aminoglycoside block of P2X2 receptors heterologously expressed in Xenopus laevis oocytes.

Authors:  Eva-Verena Bongartz; Jürgen Rettinger; Ralf Hausmann
Journal:  Purinergic Signal       Date:  2010-11-16       Impact factor: 3.765

8.  Response of mechanosensory hair cells of the zebrafish lateral line to aminoglycosides reveals distinct cell death pathways.

Authors:  Kelly N Owens; Allison B Coffin; Lisa S Hong; Keri O'Connell Bennett; Edwin W Rubel; David W Raible
Journal:  Hear Res       Date:  2009-03-11       Impact factor: 3.208

9.  Gentamicin is primarily localized in vestibular type I hair cells after intratympanic administration.

Authors:  Sofia Lyford-Pike; Casey Vogelheim; Eugene Chu; Charles C Della Santina; John P Carey
Journal:  J Assoc Res Otolaryngol       Date:  2007-09-25

Review 10.  Aminoglycosides--50 years on.

Authors:  E J Begg; M L Barclay
Journal:  Br J Clin Pharmacol       Date:  1995-06       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.